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Earlier Studies 
Successful treatment with human growth 
hormone (hGH) was initially reported by 
Raben in 19581. Although itis well estab- 
lished that pituitary derived or biosyn- 
thetic hGH increases the growth rate in 
growth hormone deficient children, 
many patients that were treated in the 
early days have not reached their target 
height, or attained adult height below the 
third percentile of population standards 2" 
5. Several explanation have been sug- 
gested for these disappointing results. In 
the earlier days treatment was started at a 
rather late age and therefore a substantial 
growth potential has been lost already. 
Several investigators found positive cor- 
relation between final height, height 
standard deviation score (SDS) for 
chronological ge (CA) or bone age (BA) 
and height at the start of treatment, 
stressing the importance of early diagno- 
sis and treatment to prevent further loss 
of height 3'4'6. 
Another contributing factor might be 
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that GH treatment shortens the duration 
of puberty and consequently the duration 
of the pubertal growth spurt. In a recent 
studyin the United Kingdom the pubertal 
parameters of 1~4 children with isolated 
GH deficiency treated with GH were 
evaluated retrospectively. The duration 
of puberty was significantly shorter com- 
pared with corresponding ormal values 
for girls and boysT. Bourgui:gnon and co- 
workers found a highly significant posi- 
tive correlation between adult height and 
the height at the start of pubertal develop- 
ment 8. Therefore attempts should be 
made to improve height before puberty 
starts. When puberty start;s while the 
child is still very short we mi!ght consider 
to give gonadotTopin-releasing hormone 
analogues inaddition to GH treatment in
order to postpone puberty and thereby 
improve final height. 
In the past, because of the ~limited sup- 
ply of pituitary derived GH, the doses of 
GH and frequencies of administration 
were low and varied among the various 
groups in different countries. Some of the 
earlier esults are shown in Table 1. In the 
Netherlands, the initial weekly dosage of 
GH was approximately 8 IU divided over 
two intramuscular (i.m.) injections. All 
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TABLE 1. Height Velocities During Growth Hormone Treatment 
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Author GH dosage per week No. of Height velocity (cm/year, mean (SD) 
IU frequency patients before year1 year2 year3 year4 
Trygstad 9 
1968 
Tanner 10 
1971 
Frasier 11 
1977 
Ranke 2 
1979 
Verbeek 12 
1979 
8-16 1-2 20 2.8 9.7 5.8 5.3 5.0 
(n=13) (n=9) (n r-6) 
20 2 35 3.1+0.2 9.1+0.5 
2.7/m 2 b.s 0 3 12 3.5+0.4 6.4+0.4 4.8+0.4 
(n=9) 
5.4/m 2 b.s 0 3 16 3.6+0.4 7.3+_0.4 5.8+__0.4 
(n=14) 
8-12 2-3 36 3.7+1.1 7.7+2.4 6.0+2.2 5.4+2.2 5.1+2.0 
(n~2.5) (n~36) (n~33) (n=22) (n=19) 
8 2 38 3.1 7.9 6.1 5.0 4.2 
(n=24) (n=12) 
0 estimated from data given 
patients received the same amount of GH 
irrespective of age, height, weight or 
body surface 12. Most studies howed that 
after an initial period of supra normal 
growth ("catch-up') with GH therapy, 
growth velocity settles back to values 
close to normal for age. 
Recent Studies 
Therefore, it is reasonable to assume that 
not only diagnosis and treatment but also 
optimization of dosage and methods of 
administration f GH will improve final 
height. Several groups, in and outside 
Europe, showed a quantitative r lation- 
ship between the GH dosage and the 
growth response to GH replace- 
ment 13-16. However, others questioned 
such dose-response relationship 17. Up to 
the mid-eighties the frequency of two, or 
three i.m. injections weekly was chosen 
based on clinical observations of the 
growth response. It was, however, a 
compromise between growth rate, the 
availability ofhGH and the amount of GH 
in each ampoule and cost/benefit calcula- 
tions. Studies in rats showed the impor- 
tance for optimal growth with more fre- 
quent GH administration 18-2~ Moreover, 
GH is secreted in episodic bursts over 
both day and night in normally growing 
children and therefore at least daily ad- 
ministration appears to be more physio- 
logical. 
Christiansen and co-workers howed 
that subcutaneous (s.c.) injections of 2 IU 
GH per square meter body surface given 
daily in the evening to GHD children re- 
suited in plasma GH concentrations, 
which approximated the average noctur- 
nal plasma patterns of normal growing 
children 21. Later on it was demonstrated 
that daily s.c. GH injections instead of 
twice or thrice weekly i.m. injections re- 
suited in a higher growth rate at least in 
the first year of study 22,23. Based upon 
these findings the currently used treat- 
ment schedule for GHD children in the 
Netherlands in 2 IU hGH/m2 b.s./day ad- 
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ministered s.c. 
Multi-Centric Dose-Response Study 
The availability of an almost unlimited 
supply of recombinant DNA-synthesized 
human GH enabled further studies on the 
dose-response r lationship in GH treat- 
ment. In 1987 we started a collaborative 
multi-center dose response study in pre- 
pubertal GHD children in the Nether- 
lands. The aims of the study were to as- 
sess the efficacy and safety of two differ- 
ent doses of authentic biosynthetic hu- 
man growth hormone in children with 
GHD and to compare the effect of two 
doses GH on clinical, auxological and 
biochemical parameters. Two groups of 
prepubertal GHD children with isolated 
or multiple pituitary b-hGH hormone 
deficiencies were formed. Group I con- 
sisted of patients previously treated with 
b-hGH for at least one year and for at least 
half a year on fixed dosage (12IU/m 2b.s./ 
week s.c.) i.e. transfer patients. Group lI 
consisted of newly diagnosed GHD chil- 
dren. The patients of both groups were 
randomly assigned to treatment with ei- 
ther 2 1U or 4 IU biosynthetic GH per 
square metre bodysurface administered 
s.c. in a daily dosage. For children with 
multiple pituitary hormone deficiencies 
adequate replacement doses of thyroxine 
and/or hydrocortisone were used. 
The results of the first two years of 
study are submitted for publication. The 
auxologicai f ndings can be summarized 
as follows : 
(i) In previously treated prepubertal 
GHD patients the increase of theGH dos- 
age up to 4 IU/m 2 b.s./day s.c. resulted 
not only in a renewed catch-up growth in 
the first year of study but also in a sus- 
tained increase in height velocity (HV), 
HV SDS, height SDS and predicted adult 
height in the second year significantly 
higher than with 2 IU/m 2. The advance in 
bone maturation was comparable for the 
two dosage groups. 
(ii) In newly diagnosed GHD pa- 
tients one year GH therapywith both 2 FU 
and 4 IU/m2/day s.c. resulted in a signifi- 
cant increase in HV, t-IV SDS and height 
SDS for CA and BA. 
(iii) If not only the GH dosage but also 
the pretreatment maximal plasma GH 
value after pharmacological stimulation 
is taken into account, the higher dosage of 
4 IU/m 2 has a significant better effect on 
the growth response than 2 IU/m 2. 
(iv) The change of height SDS for BA 
compared with pretreatment was signifi- 
cantly higher with 4 IU than with 2 IU GH/ 
m2b.s./day. Although these first year re- 
sults point to a better growth effect with 4 
IU than with 2 IU, also in newly diag- 
nosed GHD patients, the second and sub- 
sequent years of treatment have to be 
awaited to draw further conclusions. 
CONCLUSION 
It is obvious that the results published so 
far as well as the present preliminary data 
do not answer many questions regarding 
the optimal therapeutic regimen in GH 
deficiency. In particular, long-term fol- 
low-up must be organized to evaluate f- 
ficacy and safety of GH therapy not only 
in GHD but also for the "new" indica- 
tions such as Turner syndrome, short 
stature without classical GH deficiency 
and chronic renal failure. 
Finally the high expectations and the 
high costs of longterm GH treatment 
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shou ld  rece ive  full cons iderat ion .  
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